Features

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

Certain members of the House Committee on Oversight and Accountability have initiated an investigation into three long-standing, separate drug shortages, respectively seeking input from Teva, Sandoz, and Pfizer on their responses to their shortages and related manufacturing issues.

What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights takes an inside look.

The FDA’s inspection process for foreign drug-manufacturing facilities came under scrutiny once again with Congress holding a hearing questioning the frequency and quality of FDA’s foreign drug inspections. What may be next?

The CDMO/CMO sector had a major shakeup with Novo Holdings, the parent company of Novo Nordisk, announcing it had agreed to acquire Catalent for $16.5 billion. What is the strategy behind the deal and the implications on a manufacturing basis?

Which CDMOs/CDMO are expanding manufacturing capacity for intermediates and small-molecule active pharmaceutical ingredients (APIs)? DCAT Value Chain Insights gives a roundup of recently announced, in-progress, and completed expansions.

How did the industry fare with new drug approvals in 2023? What do the numbers show? Are approvals in pace with prior years, and what is the mix between small molecules and biologics? Which companies and products made the mark?

The US government is sending initial offers to participating bio/pharmaceutical companies of the first 10 Rx drugs selected for negotiation in the first cycle of the Medicare Drug Price Negotiation Program. Which companies & products are affected? 

Which companies will be making the news this year—from manufacturing expansions, to mergers & acquisitions, to other key strategic developments? Be among the newsmakers at The DCAT Member Company Announcement Forum at DCAT Week. Applications close Monday February 5.

What are they key issues impacting bio/pharmaceutical manufacturing & supply in 2024? What technology may be a game-changer or moves that will be most noteworthy across the bio/pharma manufacturing value chain? DCAT Value Chain Insights takes an inside look.